Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1437P - Clinical and economic burden of tissue re-biopsy (TRB) vs. tissue followed by liquid biopsy (TFLB) in metastatic non-small cell lung cancer (mNSCLC) patients

Date

21 Oct 2023

Session

Poster session 20

Topics

Cancer Diagnostics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Nicole Engel-Nitz

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

N.M. Engel-Nitz1, A. Shah2, J. Apple2, S. Aslam1, L. Le1, M. Terpenning3

Author affiliations

  • 1 Heor, Optum, 55344 - Eden Prairie/US
  • 2 Heor, AstraZeneca Pharmaceuticals LP, 20878 - Gaithersburg/US
  • 3 ., Marilou Terpening, M.D., LTD., 83616 - Eagle/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1437P

Background

Tissue biopsy (TIB) is the gold standard for biomarker testing in mNSCLC patients. Although TIB is common, it is associated with potential invasive procedure-related complications. Liquid biopsies are used when tissue is unavailable or insufficient for testing. Studies suggest that TFLB has comparable diagnostic accuracy to TIB for detecting genetic alterations in mNSCLC patients. Liquid biopsies are increasingly used to genotype a tumor in a less invasive manner. This study compared TIB-related complications and healthcare costs with TRB vs. TFLB in mNSCLC patients.

Methods

US administrative claims were assessed retrospectively for patients diagnosed with mNSCLC between July 2016 to June 2021 to identify adult Medicare Advantage or commercially insured patients with ≥2 biopsy claims, and whose first biopsy was tissue-based. The second biopsy defined the cohorts: TRB or TFLB. To control for possible confounding factors, study cohorts were matched 1:1 using propensity-scores (PSM).

Results

The study comprised 470 patients post-PSM, each group had 235 patients. TFLB had a lower TIB-related complication rate and associated healthcare costs compared with TRB (Table). Furthermore, mean number of complication-related healthcare visits were lower for TFLB than TRB group; outpatient visits (0.51 v 1.12, p=0.002), inpatient stays (0.45 v 0.67, p<0.001) and inpatient days (3.49 v 6.60, p=0.002). Table: 1437P

Comparison of outcomes between study cohorts

TFLB (N = 235) TRB (N = 235)
TIB-related complications (%)* 65.1 84.7
Pneumothorax* 17.5 46.0
Prolonged air leak >5 days* 1.3 11.9
Hemorrhage 14.0 18.3
Infection* 23.0 31.9
Thrombotic complications 13.2 8.5
Cardiovascular complications 38.7 42.1
Death 0.4 2.6
Mean [SD] TB complication-related healthcare costs - US$
Medical costs* 8,494 [15,706] 19,741 [30,641]
Office visits* 20 [71] 51 [219]
Outpatient visits 251 [1,672] 336 [1,562]
Emergency room visits 119 [590] 85 [358]
Inpatient stays* 8,076 [15,338] 18,918 [30,012]
Other medical costs 29 [148] 352 [3622]

∗P-value <0.05

Conclusions

The analysis suggests that TFLB, compared with traditional TRB, is a method that carries less economic burden and fewer TIB-related complications to detect actionable genetic mutations during mNSCLC diagnostic work-up.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Optum.

Funding

AstraZeneca.

Disclosure

N.M. Engel-Nitz: Financial Interests, Personal, Stocks/Shares: United Health Group; Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Research Funding, Optum received funding from AstraZeneca to complete study: AstraZeneca. A. Shah, J. Apple: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. S. Aslam: Financial Interests, Personal, Stocks/Shares: United Health Group; Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Research Funding, Optum received funding from AstraZeneca to complete study: AstraZeneca. L. Le: Financial Interests, Personal, Full or part-time Employment: Optum; Financial Interests, Institutional, Research Funding, Optum received funding from AstraZeneca to complete study: AstraZeneca; Financial Interests, Personal, Stocks/Shares: United Health Group. M. Terpenning: Financial Interests, Personal, Financially compensated role: Optum; Financial Interests, Personal, Stocks/Shares: Johnson & Johnson, Stryker.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.